DDInter837 DDInter131
Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®.
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers.[A18493,L7489] This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was granted FDA approval on 18 October 2016. In November 2022, the manufacturer (Genentech) voluntarily withdrew the use of atezolizumab for the treatment of urothelial carcinoma, previously approved under the FDA's Accelerated Approval Program. The rest of atezolizumab indications remain unaffected.
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Golimumab {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nifedipine
Golimumab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diiodohydroxyquinoline
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Cyclophosphamide
Golimumab {u} may lead to a major life threatening interaction when taken with {v} Avapritinib
Golimumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Golimumab may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Nifedipine
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Diiodohydroxyquinoline
Golimumab may lead to a major life threatening interaction when taken with Cyclophosphamide
Golimumab may lead to a major life threatening interaction when taken with Avapritinib